| [1] |
ORSI E, GRANCINI V, MENINI S, et al. Hepatogenous diabetes: Is it time to separate it from type 2 diabetes?[J]. Liver Int, 2017, 37(7): 950-962. DOI: 10.1111/liv.13337 |
| [2] |
GARCÍA-COMPEÁN D, GONZÁLEZ-GONZÁLEZ JA, LAVALLE-GONZÁLEZ FJ, et al. Hepatogenous diabetes: Is it a neglected condition in chronic liver disease?[J]. World J Gastroenterol, 2016, 22(10): 2869-2874. DOI: 10.3748/wjg.v22.i10.2869 |
| [3] |
KUMAR R. Hepatogenous diabetes: An underestimated problem of liver cirrhosis[J]. Indian J Endocrinol Metab, 2018, 22(4): 552-559. DOI: 10.4103/ijem.IJEM_79_18 |
| [4] |
LIU L, JIANG YY, LIU J. Glucose metabolism and insulin secretion in patients with chronic hepatitis B cirrhosis of different Child-Pugh grades and their association with inflammatory response[J]. J Clin Hepatol, 2020, 36(2): 324-328. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2020.02.018 |
| [5] |
GRANCINI V, TROMBETTA M, LUNATI ME, et al. Contribution of β-cell dysfunction and insulin resistance to cirrhosis-associated diabetes: Role of severity of liver disease[J]. J Hepatol, 2015, 63(6): 1484-1490. DOI: 10.1016/j.jhep.2015.08.011 |
| [6] |
NISHIDA T, TSUJI S, TSUJⅡ M, et al. Oral glucose tolerance test predicts prognosis of patients with liver cirrhosis[J]. Am J Gastroenterol, 2006, 101(1): 70-75. DOI: 10.1111/j.1572-0241.2005.00307.x |
| [7] |
MVLLER MJ, PIRLICH M, BALKS HJ, et al. Glucose intolerance in liver cirrhosis: Role of hepatic and non-hepatic influences[J]. Eur J Clin Chem Clin Biochem, 1994, 32(10): 749-758.
|
| [8] |
GRANCINI V, TROMBETTA M, LUNATI ME, et al. Central role of the β-cell in driving regression of diabetes after liver transplantation in cirrhotic patients[J]. J Hepatol, 2019, 70(5): 954-962. DOI: 10.1016/j.jhep.2019.01.015 |
| [9] |
OKITA K, IWAHASHI H, KOZAWA J, et al. Usefulness of the insulin tolerance test in patients with type 2 diabetes receiving insulin therapy[J]. J Diabetes Investig, 2014, 5(3): 305-312. DOI: 10.1111/jdi.12143 |
| [10] |
PERSEGHIN G, MAZZAFERRO V, SERENI LP, et al. Contribution of reduced insulin sensitivity and secretion to the pathogenesis of hepatogenous diabetes: Effect of liver transplantation[J]. Hepatology, 2000, 31(3): 694-703. DOI: 10.1002/hep.510310320 |
| [11] |
KAWAGUCHI T, TANIGUCHI E, ITOU M, et al. Insulin resistance and chronic liver disease[J]. World J Hepatol, 2011, 3(5): 99-107. DOI: 10.4254/wjh.v3.i5.99 |
| [12] |
ZHAO Y, XING H, WANG X, et al. Management of diabetes mellitus in patients with chronic liver diseases[J]. J Diabetes Res, 2019, 2019: 6430486.
|
| [13] |
HONG YS, CHANG Y, RYU S, et al. Hepatitis B and C virus infection and diabetes mellitus: A cohort study[J]. Sci Rep, 2017, 7(1): 4606. DOI: 10.1038/s41598-017-04206-6 |
| [14] |
|
| [15] |
ANDRES J, BARROS M, ARUTUNIAN M, et al. Treatment of hepatitis C virus and long-term effect on glycemic control[J]. J Manag Care Spec Pharm, 2020, 26(6): 775-781.
|
| [16] |
SINGHAL A, AGRAWAL A, LING J. Regulation of insulin resistance and type Ⅱ diabetes by hepatitis C virus infection: A driver function of circulating miRNAs[J]. J Cell Mol Med, 2018, 22(4): 2071-2085. DOI: 10.1111/jcmm.13553 |
| [17] |
WANG CC, CHENG PN, KAO JH. Systematic review: Chronic viral hepatitis and metabolic derangement[J]. Aliment Pharmacol Ther, 2020, 51(2): 216-230. DOI: 10.1111/apt.15575 |
| [18] |
CHEN J, WANG F, ZHOU Y, et al. Chronic hepatitis C virus infection impairs insulin secretion by regulation of p38δ MAPK-dependent exocytosis in pancreatic β-cells[J]. Clin Sci (Lond), 2020, 134(5): 529-542. DOI: 10.1042/CS20190900 |
| [19] |
CAI C, ZENG J, WU H, et al. Association between hepatitis B virus infection and diabetes mellitus: A meta-analysis[J]. Exp Ther Med, 2015, 10(2): 693-698. DOI: 10.3892/etm.2015.2537 |
| [20] |
HUANG YW, WANG TC, LIN SC, et al. Increased risk of cirrhosis and its decompensation in chronic hepatitis B patients with newly diagnosed diabetes: A nationwide cohort study[J]. Clin Infect Dis, 2013, 57(12): 1695-1702. DOI: 10.1093/cid/cit603 |
| [21] |
CHRISTEN V, TREVES S, DUONG FH, et al. Activation of endoplasmic reticulum stress response by hepatitis viruses up-regulates protein phosphatase 2A[J]. Hepatology, 2007, 46(2): 558-565. DOI: 10.1002/hep.21611 |
| [22] |
THALER FS, BANGOL B, BILJECKI M, et al. Possible link of genetic variants to autoimmunity in GAD-antibody-associated neurological disorders[J]. J Neurol Sci, 2020, 413: 116860. DOI: 10.1016/j.jns.2020.116860 |
| [23] |
NISHIMURA A, MATSUMURA K, KIKUNO S, et al. Slowly Progressive type 1 diabetes mellitus: Current knowledge and future perspectives[J]. Diabetes Metab Syndr Obes, 2019, 12: 2461-2477. DOI: 10.2147/DMSO.S191007 |
| [24] |
KUMAR K, MEHERSHAHI S, CHIME C, et al. Glycogen hepatopathy: A rare and underrecognized cause of recurrent transaminitis in patients with uncontrolled type 2 diabetes mellitus[J]. Case Rep Gastroenterol, 2018, 12(2): 466-472. DOI: 10.1159/000492205 |
| [25] |
LI HF, LIU K, ZHANG H. Changes and clinical significance of serum glutamate decarboxylase antibodies and insulin concentration in patients with hepatogenic diabetes[J]. J Clin Exp Med, 2019, 18(14): 1513-1516. (in Chinese) DOI: 10.3969/j.issn.1671-4695.2019.14.016 |
| [26] |
ELKRIEF L, RAUTOU PE, SARIN S, et al. Diabetes mellitus in patients with cirrhosis: Clinical implications and management[J]. Liver Int, 2016, 36(7): 936-948. DOI: 10.1111/liv.13115 |
| [27] |
LI X, YAO QY, LIU HC, et al. Placental growth factor silencing ameliorates liver fibrosis and angiogenesis and inhibits activation of hepatic stellate cells in a murine model of chronic liver disease[J]. J Cell Mol Med, 2017, 21(10): 2370-2385. DOI: 10.1111/jcmm.13158 |
| [28] |
NOVO E, BOCCA C, FOGLIA B, et al. Liver fibrogenesis: Un update on established and emerging basic concepts[J]. Arch Biochem Biophys, 2020, 689: 108445. DOI: 10.1016/j.abb.2020.108445 |
| [29] |
VLASSARA H, URIBARRI J. Advanced glycation end products (AGE) and diabetes: Cause, effect, or both?[J]. Curr Diab Rep, 2014, 14(1): 453. DOI: 10.1007/s11892-013-0453-1 |
| [30] |
SEBEKOVÁ K, KUPCOVÁ V, SCHINZEL R, et al. Markedly elevated levels of plasma advanced glycation end products in patients with liver cirrhosis - amelioration by liver transplantation[J]. J Hepatol, 2002, 36(1): 66-71. DOI: 10.1016/S0168-8278(01)00232-X |
| [31] |
PACKER M. Role of deranged energy deprivation signaling in the pathogenesis of cardiac and renal disease in states of perceived nutrient overabundance[J]. Circulation, 2020, 141(25): 2095-2105. DOI: 10.1161/CIRCULATIONAHA.119.045561 |
| [32] |
KIETZMANN T. Liver zonation in health and disease: Hypoxia and hypoxia-inducible transcription factors as concert masters[J]. Int J Mol Sci, 2019, 20(9): 2347. DOI: 10.3390/ijms20092347 |
| [33] |
SATO Y, TSUYAMA T, SATO C, et al. Hypoxia reduces HNF4α/MODY1 protein expression in pancreatic β-cells by activating AMP-activated protein kinase[J]. J Biol Chem, 2017, 292(21): 8716-8728. DOI: 10.1074/jbc.M116.767574 |
| [34] |
NATH B, SZABO G. Hypoxia and hypoxia inducible factors: Diverse roles in liver diseases[J]. Hepatology, 2012, 55(2): 622-633. DOI: 10.1002/hep.25497 |
| [35] |
YI P, PARK JS, MELTON DA. Betatrophin: A hormone that controls pancreatic β cell proliferation[J]. Cell, 2013, 153(4): 747-758. DOI: 10.1016/j.cell.2013.04.008 |
| [36] |
ARIAS-LOSTE MT, GARCÍA-UNZUETA MT, LLERENA S, et al. Plasma betatrophin levels in patients with liver cirrhosis[J]. World J Gastroenterol, 2015, 21(37): 10662-10668. DOI: 10.3748/wjg.v21.i37.10662 |
| [37] |
LI S, LIU D, LI L, et al. Circulating betatrophin in patients with type 2 diabetes: A Meta-analysis[J]. J Diabetes Res, 2016, 2016: 6194750.
|
| [38] |
ABU-FARHA M, ABUBAKER J, TUOMILEHTO J. ANGPTL8 (betatrophin) role in diabetes and metabolic diseases[J]. Diabetes Metab Res Rev, 2017, 33(8): 19-29.
|
| [39] |
LEE SH, RHEE M, KWON HS, et al. Serum betatrophin concentrations and the risk of incident diabetes: A nested case-control study from chungju metabolic disease cohort[J]. Diabetes Metab J, 2018, 42(1): 53-62. DOI: 10.4093/dmj.2018.42.1.53 |
| [40] |
HU H, SUN W, YU S, et al. Increased circulating levels of betatrophin in newly diagnosed type 2 diabetic patients[J]. Diabetes Care, 2014, 37(10): 2718-2722. DOI: 10.2337/dc14-0602 |
| [41] |
CHRISTENSEN AS, HÆDERSDAL S, STORGAARD H, et al. GIP and GLP-1 potentiate sulfonylurea-induced insulin secretion in hepatocyte nuclear factor 1α mutation carriers[J]. Diabetes, 2020, 69(9): 1989-2002. DOI: 10.2337/db20-0074 |
| [42] |
ITOU M, KAWAGUCHI T, TANIGUCHI E, et al. Dipeptidyl peptidase-4: A key player in chronic liver disease[J]. World J Gastroenterol, 2013, 19(15): 2298-2306. DOI: 10.3748/wjg.v19.i15.2298 |
| [43] |
ASO Y, KATO K, SAKURAI S, et al. Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease[J]. Int J Clin Pract, 2019, 73(5): e13335. DOI: 10.1111/ijcp.13335 |
| [44] |
DEACON CF. Corrigendum: Physiology and pharmacology of DPP-4 in Glucose homeostasis and the treatment of type 2 diabetes[J]. Front Endocrinol (Lausanne), 2019, 10: 275. DOI: 10.3389/fendo.2019.00275 |
| [45] |
BERINGER A, MIOSSEC P. IL-17 and TNF-α co-operation contributes to the proinflammatory response of hepatic stellate cells[J]. Clin Exp Immunol, 2019, 198(1): 111-120. DOI: 10.1111/cei.13316 |
| [46] |
BUECHLER C, HABERL EM, REIN-FISCHBOECK L, et al. Adipokines in liver cirrhosis[J]. Int J Mol Sci, 2017, 18(7) : 1392. DOI: 10.3390/ijms18071392 |
| [47] |
BOUTARI C, TZIOMALOS K, ATHYROS VG. The adipokines in the pathogenesis and treatment of nonalcoholic fatty liver disease[J]. Hippokratia, 2016, 20(4): 259-263.
|
| [48] |
ARAI Y, KAMIDE K, HIROSE N. Adipokines and aging: Findings from centenarians and the very old[J]. Front Endocrinol (Lausanne), 2019, 10: 142. DOI: 10.3389/fendo.2019.00142 |
| [49] |
MOUSA N, ABDEL-RAZIK A, SHETA T, et al. Serum leptin and homeostasis model assessment-IR as novel predictors of early liver fibrosis in chronic hepatitis B virus infection[J]. Br J Biomed Sci, 2018, 75(4): 192-196. DOI: 10.1080/09674845.2018.1505187 |
| [50] |
GUO Y, LIU L, WANG J. Adiponectin and the risk of new-onset atrial fibrillation: A meta-analysis of prospective cohort studies[J]. Biosci Rep, 2019, 39(6): BSR20182284. DOI: 10.1042/BSR20182284 |
DownLoad: